Executive Summary

Comments of John Coates, Founder of RF Safe

Regarding Non-Thermal, Nonlinear, and Tissue-Specific EMF Risk, Public Law 90-602, and the FCC’s Unresolved RF Exposure Remand

nonthermal_emf_comments_updated.pdf

These comments are submitted by John Coates, Founder of RF Safe, to address a critical defect in the FCC’s continuing reliance on outdated radiofrequency exposure assumptions while proposing to accelerate and preempt local review of wireless infrastructure. The existing record already explains that artificial electromagnetic radiation is physical energy, that modulated and pulsed emissions differ materially from continuous-wave exposures, that multiple simultaneous emissions must be evaluated in aggregate, and that current FCC exposure rules remain centered on time-averaged heating metrics rather than biologically relevant signal structure. The purpose of this Executive Summary is to identify why recent scientific developments make further delay legally and scientifically indefensible.

The D.C. Circuit has already remanded the FCC’s RF exposure decision because the Commission failed to provide a reasoned explanation that its 1996-era guidelines adequately protect against harmful effects of RF exposure unrelated to cancer. The court specifically recognized that RF radiation at lower levels may cause biological effects and held that the FCC had not adequately justified its continued reliance on the existing framework. The FCC therefore should not expand federal preemption, accelerate “deemed granted” approvals, or further constrain local review while the underlying exposure framework remains unresolved.

The central scientific question is no longer whether radiofrequency radiation can heat tissue. It can. The unresolved question is whether modern wireless emissions—pulsed, modulated, polarized, coherent, variable, beamformed, and emitted from multiple simultaneous sources—can perturb non-thermal biological signaling systems at levels below existing thermal limits. Recent science has made that question more concrete, not less. It now identifies specific, testable biological mechanisms that federal agencies are legally obligated to investigate.

First, the S4 voltage-sensor framework provides a nanoscale mechanism by which low-frequency components of electromagnetic fields may influence voltage-gated ion-channel timing. Panagopoulos et al. describe wireless communication fields as microwave carrier waves modulated by extremely-low-frequency signals and included in on/off pulses repeated at ELF rates, with additional ultra-low-frequency variability. They further identify voltage-gated ion-channel dysfunction, calcium disturbance, mitochondrial electron-transport effects, NADPH/NADH oxidase pathways, nitric-oxide synthase pathways, reactive oxygen species, and oxidative stress as a proposed mechanistic chain. This does not prove that every wireless exposure causes disease. It does, however, show that a thermal-only framework does not answer the relevant biological question.

Second, the 2026 Cell paper materially changes the evidentiary posture by identifying cytochrome b5 type B, CYB5B, as an essential mediator likely acting as an electromagnetic-field sensor in an EMF-inducible in vivo gene-switch system. The Cell summary states that CYB5B mediates EMF-specific calcium oscillations for gene-switch activation. That finding is not proof that ordinary Wi-Fi or cellular exposure causes any particular disease. Its importance is narrower and stronger: it supplies a specific mitochondrial membrane-associated protein target that can now be tested under wireless-relevant exposure conditions. Before CYB5B, agencies could claim that non-thermal weak-field biology lacked a defined molecular transducer. After CYB5B, that answer is no longer adequate.

Third, the S4 and CYB5B pathways converge on a common biological risk concept: loss of signaling fidelity. Calcium signaling is not merely a question of total calcium concentration. It is a timing code. Frequency, amplitude, phase, localization, burst structure, and recovery kinetics can determine downstream gene expression, mitochondrial function, neuronal excitability, cardiac rhythm, immune signaling, and redox state. The proper question for HHS and FCC is therefore whether modern wireless emissions can act as timing perturbagens—physical exposures that degrade the fidelity of calcium, ion-channel, mitochondrial, and redox signaling without requiring bulk tissue heating.

Fourth, tissue-specific vulnerability may be governed by what these comments identify as density gating. Under this hypothesis, susceptibility is not uniform throughout the body; it may be greatest in tissues with high densities of S4-bearing voltage-gated channels, mitochondria, CYB5B/redox machinery, calcium-handling systems, and excitable membranes. This matters because the animal evidence has repeatedly raised concern in heart and nervous-system tissues. A WHO-commissioned systematic review of experimental-animal cancer studies included 52 studies and found high certainty of evidence for increased glioma risk in male rats and high certainty for increased malignant heart schwannomas in male rats, while also recognizing that extrapolation to humans is complex and depends on mechanism, exposure metric, cumulative exposure, dose-response, and whether SAR is the correct adverse-effect metric. Density gating gives HHS a specific hypothesis to test: whether tissues rich in excitable membrane, mitochondrial, calcium, and redox machinery are more vulnerable to non-thermal timing disruption.

Fifth, the Ramazzini genetic-profiling evidence strengthens the need for investigation. Brooks et al. examined rat gliomas and cardiac schwannomas from the Ramazzini lifetime RFR study using a targeted next-generation sequencing panel. Their abstract states that the rat gliomas histologically resembled low-grade human gliomas, appeared to share some genetic alterations with IDH1-wildtype human gliomas, and that rat cardiac schwannomas also harbored mutations in queried cancer genes. This does not establish human causation. It does undercut any categorical dismissal of rodent glioma and cardiac schwannoma findings as irrelevant artifacts.

Sixth, EPA-style toxicological risk assessment further demonstrates that existing limits cannot simply be assumed adequate. Melnick, Moskowitz, and ICBE-EMF report that recent WHO-commissioned systematic reviews concluded with high certainty that RF-EMF exposure increases cancer risk and reduces male fertility in experimental animals. They applied benchmark-dose and uncertainty-factor methods and concluded that current public whole-body SAR limits are 15- to 900-fold higher than their cancer-risk estimates and 8- to 24-fold higher than levels they estimate as protective for male reproductive health. Whether one accepts or disputes every assumption in that analysis, it plainly requires a reasoned federal response. The FCC cannot lawfully ignore such a risk-assessment challenge while expanding reliance on the same exposure limits.

Seventh, competing evidence must be weighed transparently, including institutional conflicts and viewpoint conflicts. If the FCC cites Karipidis et al. or similar reviews to minimize non-thermal concerns, it must disclose that key authors have institutional roles within ICNIRP or closely related guideline-setting structures. ICNIRP identifies Ken Karipidis as its Vice Chair since July 2024; Dan Baaken as ICNIRP Scientific Secretary and a member of the ICNIRP Board; and Martin Röösli as a former ICNIRP Commissioner who now contributes as a Scientific Expert Group member. This does not prove misconduct. It does require disclosure and appropriate weighting, because ICNIRP’s guideline framework is part of the thermal-centered paradigm under review.

Eighth, the FDA’s TheraBionic P1 approval provides a particularly important regulatory precedent. FDA approved TheraBionic P1 under HDE H220001 as an amplitude-modulated RF EMF device for advanced hepatocellular carcinoma, and FDA’s Summary of Safety and Probable Benefit describes low-level, amplitude-modulated 27.12 MHz RF exposure at tumor-specific modulation frequencies, systemic absorption, no thermal heating, and delivered EMF levels estimated to be 100 to 1,000 times lower than those delivered by cellular phones. FDA’s labeling further states that the device should not be used in patients receiving calcium channel blockers or agents blocking L-type or T-type voltage-gated calcium channels. This does not prove that ordinary wireless exposures cause disease, but it does refute any categorical claim that non-thermal, amplitude-modulated RF effects on calcium-channel biology are biologically impossible or regulatorily irrelevant. FCC and HHS must therefore evaluate whether existing SAR and time-averaged power-density metrics adequately protect against calcium-channel, S4/VGIC, CYB5B, mitochondrial redox, and calcium-rhythm effects.

Congress has already supplied the statutory mandate. Public Law 90-602, now reflected in the Electronic Product Radiation Control provisions of the FD&C Act, applies to electronic products that contain or act as part of an electronic circuit and emit electronic product radiation. FDA defines electronic product radiation to include non-ionizing electromagnetic radiation emitted from an electronic product and lists cordless and cellular telephones as examples of covered non-medical electronic products. 21 U.S.C. § 360ii requires the Secretary of HHS to establish and carry out an electronic product radiation control program designed to protect public health and safety, including research to minimize unnecessary exposure, study and evaluation of emissions and exposure conditions, and development and testing of procedures for minimizing exposure. 21 U.S.C. § 360kk further authorizes performance standards for electronic products when necessary to protect public health and safety and requires consideration of the latest available scientific and medical data.

Accordingly, the legal and scientific question is not whether these comments have proven that wireless radiation causes a particular disease. They do not need to. The question is whether the FCC and HHS may continue to act as if heat is the only biologically relevant endpoint after the record now identifies S4 voltage sensors, CYB5B-mediated calcium oscillation, mitochondrial redox signaling, animal cancer findings, reproductive-toxicity signals, translational tumor genetics, and a testable density-gating hypothesis. The answer is no.

These comments respectfully request that the FCC not finalize any rule expanding preemption, accelerating wireless approvals, narrowing local authority, or increasing reliance on existing RF compliance determinations until the Commission has coordinated with HHS/FDA and provided a reasoned response to these non-thermal, nonlinear, pulsed, modulated, aggregate, and tissue-specific mechanisms. At minimum, HHS and FCC must determine whether SAR and time-averaged power density are sufficient metrics for biological endpoints governed by calcium rhythm, ion-channel gating, mitochondrial redox state, nitric-oxide signaling, gene-expression control, and tissue-specific density gating.

The agencies should immediately fund and require blinded, sham-controlled, independently replicated research testing CYB5B knockout/knockdown/rescue models, S4/VGIC involvement, telecom-like modulation envelopes, Wi-Fi beacon periodicity, GSM-like 217 Hz repetition, LTE/5G duty-cycle and beamforming patterns, mitochondrial redox endpoints, calcium rhythm fidelity, and aggregate multi-source exposure at everyday and FCC-compliant levels. The research agenda should prioritize cardiomyocytes, neurons, glia, Schwann cells, reproductive cells, immune cells, and other tissues with high excitable-membrane, mitochondrial, calcium-handling, and redox density.

The FCC cannot cure the D.C. Circuit remand by repeating that current limits prevent excessive heating. That was the old question. The current record demands a new answer: whether the federal exposure framework protects the public from non-thermal, nonlinear, timing-dependent, aggregate, and tissue-specific biological disruption. Until HHS and FCC answer that question using the latest science, transparent conflict disclosure, and the statutory tools Congress already provided in Public Law 90-602, expanding wireless deployment preemption would be premature, arbitrary, and contrary to the public-health mandate embedded in federal law.